Inactive Instrument

Analyst Reco. Ligand Pharmaceuticals Inc. OTC Bulletin Board

Equities

US53220K1815

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

27/06	Ligand Pharmaceuticals' Partner Gets US FDA Approval for Ohtuvayre to Treat Chronic Obstructive Pulmonary Disease	MT
18/06	Merck Receives FDA Approval for Capvaxive, Triggers $2 Million Payment for Ligand Pharmaceuticals	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Ligand Pharmaceuticals Insider Sold Shares Worth $830,449, According to a Recent SEC Filing	14/05	MT
Barclays Cuts Price Target on Ligand Pharmaceuticals to $110 From $120, Maintains Overweight Rating	25/23/25	MT
Roth Capital Boosts Price Target on Ligand Pharmaceuticals to $90 From $85, Maintains Buy Rating	23/22/23	MT
HC Wainwright Adjusts Ligand Pharmaceuticals Price Target to $135 From $310, Maintains Buy Rating	25/22/25	MT
Barclays Adjusts Price Target on Ligand Pharmaceuticals to $150 From $157, Reiterates Overweight Rating	25/22/25	MT
Roth Capital Partners Cuts Price Target on Ligand Pharmaceuticals to $175 From $185, Reiterates Buy Rating	02/22/02	MT
Barclays Adjusts Price Target on Ligand Pharmaceuticals to $157 From $165, Reiterates Overweight Rating	05/22/05	MT
CJS Securities Adjusts Ligand Pharmaceuticals Price Target to $145 From $210, Maintains Market Outperform Rating	14/22/14	MT
Stephens Adjusts Ligand Pharmaceuticals' Price Target to $130 from $153, Keeps Overweight Rating	16/22/16	MT
Benchmark Adjusts Ligand Pharmaceuticals' Price Target to $130 From $180, Reiterates Buy Rating	22/22/22	MT
LIGAND PHARMACEUTICALS INCORPORATED : Barclays Boosts Price Target on Ligand Pharmaceuticals to $180 From $174, Maintains Overweight Rating	22/21/22	MT
LIGAND PHARMACEUTICALS INCORPORATED : Roth Capital Adjusts Price Target on Ligand Pharmaceuticals to $190 From $200, Maintains Buy Rating	30/21/30	MT
LIGAND PHARMACEUTICALS INCORPORATED : Barclays Adjusts Price Target on Ligand Pharmaceuticals to $190 From $198, Maintains Overweight Rating	04/21/04	MT
LIGAND PHARMACEUTICALS INCORPORATED : Stephens Reinstates Ligand Pharmaceuticals at Overweight With $200 Price Target	14/21/14	MT
Treasury Markets Calm, But Investors Anticipate a Rate Rise Soon	25/21/25	DJ
LIGAND PHARMACEUTICALS INCORPORATED : Barclays Adjusts Price Target on Ligand Pharmaceuticals to $198 From $146, Reiterates Overweight Rating	04/21/04	MT
LIGAND PHARMACEUTICALS INCORPORATED : Craig-Hallum Adjusts Price Target on Ligand Pharmaceuticals to $215 From $195, Reiterates Buy Rating	04/21/04	MT
LIGAND PHARMACEUTICALS INCORPORATED : Roth Capital Adjusts Price Target on Ligand Pharmaceuticals to $200 From $195, Maintains Buy Rating	04/21/04	MT
LIGAND PHARMACEUTICALS INCORPORATED : HC Wainwright Adjusts Ligand Pharmaceuticals' Price Target to $310 From $299, Keeps Buy Rating	04/21/04	MT
Berenberg USA Conference	24/18/24	FA

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Ligand Pharmaceuticals Inc. OTC Bulletin Board

Equities

US53220K1815

Analyst Reco.

Filters